April 1, 2026 · Form 4 insider transaction
Sloan Sheldon bought 7,958 shares of Spyre Therapeutics, Inc. at $21.66 per share, a transaction worth $172.4K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.